Immunohistochemical Expression Profile of P16 In Cervical Carcinoma Patients At Siloam Mrccc Cancer Hospital In 2022
DOI:
https://doi.org/10.51601/ijhp.v6i3.351Abstract
Cervical carcinoma is a rapidly growing health issue, with global cases reaching 662,301 and causing 348,874 deaths in 2022. Almost all cervical carcinoma cases are associated with persistent Human Papillomavirus (HPV) infection. The cell cycle-dependent kinase inhibitor (p16) serves as a reliable surrogate biomarker for HPV-associated cervical carcinoma. This descriptive observational study analyzes the dataset from the academic file "Ani Oranda Panjaitan_Fajar Lamhot Gultom.docx", which examines the immunohistochemical expression profile of the p16 protein in cervical carcinoma patients at Siloam MRCCC Cancer Hospital in 2022. Out of 42 archived cases, squamous cell carcinoma (SCC) was the dominant subtype with 34 cases (81%), followed by adenocarcinoma and adenosquamous carcinoma with four cases (9.5%) each. From the 32 patients who met the strict inclusion criteria for immunohistochemical staining, 30 patients (93.75%) demonstrated positive p16 expression, confirming a high prevalence of HPV-associated cervical carcinoma. Conversely, two patients (one SCC and one adenocarcinoma) showed negative p16 results. These findings indicate that over 93% of cervical carcinoma cases at this facility are directly associated with HPV, with SCC remaining the predominant subtype. Further research is needed to expand the sample size and integrate PCR HPV genotyping to monitor viral presence.
Downloads
References
[1] Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024.
[2] Prihantono. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. Ethiop J Health Sci. 2023 May; 33(3): p. 515–22
[3] International Agency for Research on Cancer. Estimated number of new cases from 2022 to 2045, both sexes, age [0-85+], cervix uteri [Internet]. Cancer Tomorrow. 2022 [cited 2024 Nov 26].
[4] Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64-84.
[5] Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998 Mar;16(3):1197-206.
[6] Fowler JR. Cervical Cancer. National Library of Medicine [Internet]. 2022 November [cited 2023 November 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431093/
[7] Somia IKA. Prevalence of and risk factors associated with anal HPV infection among men who have sex with men in Bali, Indonesia. Bali Medical Journal (Bali Med J). 2020
[8] Wulandari D, Meidyandra RW, Andrijono. Genotype profiles of high-risk human papillomavirus in women of reproductive age: A community-based study. PLoS One. 2023 Jul 17;18(7):e0287399.
[9] Min EY, Kim IH, Lee J, Kim EY, Choi Y, Nam TJ. The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines. Int J Oncol. 2014;45(1):47-9.
[10] Münger, K et al. “Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.” Cancer surveys vol. 12 (1992): 197-217.
[11] WHO Classification of Tumours Editorial Board. WHO classification of tumours: Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020. Corrigenda updated June 2021. P 347-83
[12] Gondhowiardjo SA, Kusumadjati A, Wibisono P, Sekarutami SM. Cervical cancer profile in dr. Cipto Mangunkusumo Hospital year 2013 [Internet]. J Oncol Res Indones. 2019;10(1):14-18 [cited 2024 Nov 20].
[13] Pratiwi SE, Trianto HF, Fatinah NN, Ilmiawan MI, Fitrianingrum I, Lestari D. The profile of cervical cancer patients at Soedarso Hospital. Indones J Cancer [Internet]. 2023 [cited 2024 Oct 15];17(3):135-40.
[14] Hodgson A, Parra-Herran C. Stains & CD markers: p16 [Internet]. PathologyOutlines.com; 2017 Jul 1 [cited 2024 Oct 16].
[15] Darragh, Teresa M et al. “The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.” Archives of pathology & laboratory medicine vol. 136,10. 2012: 1266-97.
[16] Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. International Journal of Cancer. 2001;92(2):276-284.
[17] Dijkstra MG, Heideman DAM, de Roy SC, Rozendaal L, Berkhof J, van Kemenade FJ, et al. p16INK4a immunostaining as a surrogate marker for high-risk human papillomavirus infection in cervical cytology and histology: a review. Journal of Clinical Pathology. 2010;63(11):972-979.
[18] Tsuda H, Yamamoto K, Inoue T, Uchiyama M, Umesaki N. p16INK4a expression in cervical intraepithelial neoplasia and invasive carcinoma: correlation with human papillomavirus infection and clinicopathological features. Pathology International. 2007;57(9):568-575.
[19] Schaefer IM, Hornick JL, Sholl LM, Quade BJ, Nucci MR, Parra-Herran C. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. Histopathology. 2017 Jun;70(7):1138-1146. doi: 10.1111/his.13176. Epub 2017 Mar 20. PMID: 28130839
[20] Tjalma WAA, Depuydt CE. Cervical cancer screening: which HPV test should be used—liquid-based cytology, HPV DNA testing, or HPV genotyping? European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;169(2):263-269.
[21] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer. 2002;2(5):342-350.
[22] WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ani Oranda Panjaitan, Fajar Lamhot Gultom, Clariza Ovelyn Iona Rombe
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
